Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606670 | 1.00 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL605620 | 1.00 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL4937733 | 0.93 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL14026551 | 0.93 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL606841 | 0.91 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL602002 | 0.88 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL603007 | 0.88 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL14026554 | 0.88 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL4937137 | 0.86 | HRH4 (0.75) | HRH4HRH3 | |
| SCHEMBL4594943 | 0.86 | HRH4 (0.75) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885 |
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.